Abstract
Ruthenium compounds are a class of potential anticancer agents in a field with many emerging metal-based drugs and drug candidates. This work presents the synthesis and structural evaluation of a new Ru(II) complex of 3-hydroxyiminoflavanone with spectroscopic and crystallographic methods. Its cytostatic and hemostatic activity, as well as its behavior in solution, are compared with those of two previously described, cytotoxic Ru(II) complexes with C2-substituted 3-iminoflavanones. The synthesis of this compound results in the oxidation of one of the two coordinated 3-hydroxyiminoflavanones to 3-nitrosoflavone and reduction of Ru(III) to Ru(II). The obtained complex has moderate to low toxicity towards five human cancer cell lines, unlike similar ruthenium compounds. The article attempts to account for the difference on the basis of structural differences, solution UV–Vis studies and theoretical evaluation. As none of the tested compounds seriously alter hemostasis or red blood cell integrity in vitro, they might be suitable for further in vitro and in vivo testing.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
